#IEX Q3 Concall Highlights ⚡

Watch the video for better understanding

Link :

Like & Retweet for better reach !

Financial Update

1. Revenue for the quarter increased by 32.4% from 95.7 Crores in Q3 of FY2021 to 126.7 Crores in Q3 of FY2022.
2. PAT grew by 33% YoY from Rs 60.1 Cr in Q3FY21 to Rs 79.9cr in Q3FY22 with a Margin of 63.1%.

3. Revenue for the 9M FY22 increased by 37%, from Rs. 255.6 Cr. in 9M FY21 to Rs. 350.1 Cr. in 9M FY22.
4. PAT grew by 48.1% YoY from Rs 149.7 Cr in 9MFY21 to Rs 221.6 Cr in 9MFY22, with a margin of 63.3%.
POLICY AND REGULATORY UPDATES

1. On 16th December 2021, CERC issued the draft CERC (Connectivity and General Network Access to the inter-State Transmission System) Regulations, 2021.
This will simplify, ease, and clarify how transmission access will be available for participants on the Exchange.
Post implementation of GNA, decision making by market participants, to participate on the Exchange, will not be contingent upon transmission access and charges. GNA will promote the development of the power market in the country.
2. On 6th October 2021, the 10 year long pending jurisdictional conflict related to power market between CERC and SEBI was resolved paving way for the introduction of long duration contracts in power and renewable energy on the Power Exchanges.
This will also enable the launch of Electricity Derivatives on Commodity Exchanges.

3. Electricity derivatives will smoothen out the price volatility and also buyers will be able to hedge their positions and take delivery in spot markets.
This will lead to an increase in the Exchange transactions.

4. IEX has already applied for approval of longer duration contracts to CERC.
5. CERC also issued the draft Deviation Settlement Mechanism (DSM) and Related Matters Regulations, 2021, linking the DSM charges to the time block-wise price discovered on the Exchange. Implementation of this initiative will help to further deepen the real-time market.
6. The National Open Access Registry (NOAR) is also likely to be implemented in fiscal year 2022. NOAR will automate processing of open access and considerably reduce the lead time taken in the various procedures.
This will also make the transmission allocation more transparent and efficient.

POWER SECTOR HIGHLIGHTS

1. At the end of December 2021, India's renewable installed capacity was 151 gigawatt. The share of renewable energy in India's total capacity base has increased to 38%.
2. National Electricity consumption stood at 321 BU during the quarter, registering a 5% CAGR growth over the last 2 years.
Business Update

1. In the month of October due to high demand and supply constraints from the domestic coal, domestic coal inventory was only about 4 days which led to an increase in the price of electricity and their prices increased to about Rs 8.01 per unit.
However, with an increase in coal supply, the domestic coal inventory has now increased to 9 days in the month of December and their prices in the month of November were about Rs.3 and in December was Rs.3.54 paisa per unit.
2.Traded volumes on the Exchange grew by 37% YoY with 27.6 BU volumes traded versus 20.1BU in Q3 FY’21. The growth in volumes was driven by an increase in electricity consumption as well as resurgence of trading in REC’s and ESCERT’s.
3. Gujarat, Andhra Pradesh, Punjab, Maharashtra, and Haryana contributed the highest to Exchange’s electricity volumes
4. Trading in the Renewable Energy Certificates Market restarted on the 24th of November 2021 after a 16-month gap. Company seeing a very strong momentum on REC trading.
5. The Real-Time Market continues to be one of the fastest-growing electricity market segments on the Exchange, achieving a growth of 70% YoY with 4.8 BU of volumes traded during the quarter.
6. The green market, including the day ahead and term ahead market, cumulatively traded 1.2 BU during the quarter, and contributed 5% to overall electricity volumes.
7. On the REC front, a total of 38.28 lakh certificates, and a total of 2.86 lakh Energy Saving Certificates traded during the quarter
8. Cross Border Trade with Bhutan commenced in the Day-Ahead market. Company is closely working with key stakeholders in Bangladesh to garner their participation as well
9. The Exchange is now gearing to launch the Longer Duration delivery contracts in electricity and renewable segment. Company is also working on other new segments such as Exchange based Ancillary Markets, Capacity Markets as well as Gross Bidding Contracts.
IGX

1. After a sale of 4.93% stake to IOCL, IEX Holding in IGX is reduced to 47% now and now IGX is not a subsidiary company of IEX, it is an associate company of IEX
2. In Q3 2021 IGX recorded a trade volume of 3.6 million MMBTU. Cumulatively 5 million MMBTU was traded through IGX during the year.

3. IGX achieved breakeven in Q3 FY22.

4. IOCL has joined IGX as a new strategic partner.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Feb 5
#JubilantPharmova Q3 FY22 concall highlights 💊💊

Like & retweet for better reach !

1. The company’s performance for the quarter was affected by headwinds in the pharmaceutical business.
But was partly mitigated due to robust performance in the Contract Research and Development Services (CRDS) segment.
2. While the Radiopharma business showed improved performance, Generics business was affected by lower volumes due to Import Alert at Roorkee plant, latest sartan impurities issue and pricing pressure in the US generics market.
Read 14 tweets
Feb 5
#DishmanCarbogenAmcis Q3 FY22 concall highlights 💊💊

Like & Retweet for better reach !

1. They have had a very strong quarter - especially in CRAMS where the pipeline continues to be very strong.
2. They are seeing good interest and strong growth in the Vitamin D analogues.

3. The cholesterol business is stable and the disinfectant business is seeing increased interest from customers.
4. They have seen a rapid rise in transportation and logistics costs. There are also price rises in Central Europe for basic utilities like electricity, gas and water.
Read 18 tweets
Feb 5
#Balajiamines Q3 22 Concall Highlights 🧪🧪

Like & Retweet for better reach !

Operational Highlights

1. Revenues stood at ₹475 Cr in Q3FY22 compared to ₹366 Cr in Q3FY21, growth of 29.4% YoY

2. EBITDA stood at 109.3 Cr translating 23% EBITDA margins
3. Sales volumes were down by 13.77% from 31,993 MT in Q3FY21 to 27,589 MT in Q3FY22. As few of the clients couldn’t procure Key Starting Materials (KSMs) to match the products.
4. Despite sluggish demand for few of the products and shut down of acetonitrile and DMF plants for debottlenecking which were completed in the month of November 2021, the revenues showed a decent growth of 44% which stood at ₹556 Cr in Q3FY22
Read 11 tweets
Feb 5
#Dhanukaagritech Q3 22 Concall Highlights 🧪🧪

Like & Retweet for better reach !

Operational Highlights

1. Revenues from Operations stood at ₹356.86 Crores in Q3 FY2021-22 vs ₹295.66 Crores in Q3 FY2020-21.
2. EBITDA stood at ₹61.74 Cr with EBITDA margins at 17%

3. Q3FY22 revenue split - Specialty Contributed 60% & Generic contributed 40%

Products contribution to revenues

Insecticides 32%- Fungicides 19%-Herbicides 36%-Others 13%
Geography wise revenues contribution

North 21%
South 37%
East 11%
West 31%

Growth is driven by new products and largely driven by herbicides

Volume growth were 18% during the quarter (1.8% for 9MFY22) partly along with price hikes
Read 10 tweets
Feb 4
#IndocoRemedies Q3 FY22 concall highlights 💊💊

Watch the video :

Like & Retweet for better reach !
1. Net revenues for the quarter were ₹348.6 Cr (4.6% growth YoY). EBITDA for the quarter stood at ₹73.4 Cr and EBITDA margin for the quarter was 21.1%.PAT for the quarter was ₹33 Cr and PAT margins were 9.5%.
2. Revenues from domestic formulation business for the quarter was ₹181.5 Cr (15.2% growth YoY). Major therapeutic segments viz. anti-infectives, gastrointestinal, urological and respiratory performed well.
Read 25 tweets
Feb 4
#Meghmaniorganics Q3 22 Concall Highlights 🧪🧪

Like & Retweet for better reach !

Operational Highlights

1. Despite the challenging business environment, Meghmani Organics Ltd. (MOL) revenue grew by 43.7% YoY to ₹ 640 Cr in Q3 FY22 aided by higher realisation from Pigments
along with improvement in volume & higher realisation from Agrochemicals business.

2. As an industry wide phenomenon, MOL too faced the challenge in respect to hardening of raw material prices.
Due to the sudden and sharp rise of raw material prices, MOL faced a challenge in terms of fully passing on to consumers.

3. EBITDA stood at ₹77.4 Cr with 12.1% EBITDA margins from 20.2% YoY
Read 21 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

:(